James Kuo, CEO and Co-founder of Tryp Therapeutics Post published:January 15, 2021 Post category:Interview
CBDV Begins Research on Psilocybin with Section 56 Exemption from Health Canada Post published:January 14, 2021 Post category:Press Release
Mydecine Innovations Group Announces C$10 Million Bought Deal Offering of Units Post published:January 14, 2021 Post category:Press Release
Entheon Biomedical Corp. Announces Acquisition of HaluGen Life Sciences Inc. Post published:January 14, 2021 Post category:Press Release
Revive Therapeutics Announces Research Collaboration with North Carolina State University for Natural Biosynthesis Enzymatic Platform To Develop Psilocybin Post published:January 14, 2021 Post category:Press Release
MindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical Trial Experience Post published:January 14, 2021 Post category:Press Release
Tryp Therapeutics Strengthens Board of Directors With Appointment of Gregory M. McKee Post published:January 14, 2021 Post category:Press Release
NeonMind Appoints Dr. Frank Russo to Lead Development of Music-Based Program for Psilocybin Clinical Trials Post published:January 14, 2021 Post category:Press Release
Psyched Wellness Completes Initial Data Review to Determine Clinical Path for Muscimol Post published:January 14, 2021 Post category:Press Release